6/6
10:04 am
avte
Aerovate Therapeutics, Inc. (NASDAQ: AVTE) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $41.00 price target on the stock.
Medium
Report
Aerovate Therapeutics, Inc. (NASDAQ: AVTE) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $41.00 price target on the stock.
6/6
10:04 am
avte
Aerovate Therapeutics, Inc. (NASDAQ: AVTE) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $41.00 price target on the stock.
Medium
Report
Aerovate Therapeutics, Inc. (NASDAQ: AVTE) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $41.00 price target on the stock.
6/6
09:51 am
avte
Rating for AVTE
Medium
Report
Rating for AVTE
6/6
09:51 am
avte
Rating for AVTE
Medium
Report
Rating for AVTE
5/22
11:14 am
avte
Aerovate Therapeutics, Inc. (NASDAQ: AVTE) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $41.00 price target on the stock.
Medium
Report
Aerovate Therapeutics, Inc. (NASDAQ: AVTE) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $41.00 price target on the stock.
5/22
11:14 am
avte
Aerovate Therapeutics, Inc. (NASDAQ: AVTE) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $41.00 price target on the stock.
Medium
Report
Aerovate Therapeutics, Inc. (NASDAQ: AVTE) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $41.00 price target on the stock.
5/22
10:56 am
avte
Rating for AVTE
Medium
Report
Rating for AVTE
5/22
10:56 am
avte
Rating for AVTE
Medium
Report
Rating for AVTE
5/14
08:46 am
avte
Aerovate Therapeutics, Inc. (NASDAQ: AVTE) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $41.00 price target on the stock.
Low
Report
Aerovate Therapeutics, Inc. (NASDAQ: AVTE) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $41.00 price target on the stock.
5/14
08:46 am
avte
Aerovate Therapeutics, Inc. (NASDAQ: AVTE) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $41.00 price target on the stock.
Low
Report
Aerovate Therapeutics, Inc. (NASDAQ: AVTE) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $41.00 price target on the stock.
5/14
08:32 am
avte
Rating for AVTE
Low
Report
Rating for AVTE
5/14
08:32 am
avte
Rating for AVTE
Low
Report
Rating for AVTE
4/9
06:02 am
avte
Aerovate Therapeutics, Inc. (NASDAQ: AVTE) had its "outperform" rating re-affirmed by analysts at Wedbush.
Medium
Report
Aerovate Therapeutics, Inc. (NASDAQ: AVTE) had its "outperform" rating re-affirmed by analysts at Wedbush.
4/9
06:02 am
avte
Aerovate Therapeutics, Inc. (NASDAQ: AVTE) had its "outperform" rating re-affirmed by analysts at Wedbush.
Medium
Report
Aerovate Therapeutics, Inc. (NASDAQ: AVTE) had its "outperform" rating re-affirmed by analysts at Wedbush.
4/1
12:17 pm
avte
Aerovate Therapeutics, Inc. (NASDAQ: AVTE) had its "overweight" rating re-affirmed by analysts at Wells Fargo & Company. They now have a $35.00 price target on the stock.
Medium
Report
Aerovate Therapeutics, Inc. (NASDAQ: AVTE) had its "overweight" rating re-affirmed by analysts at Wells Fargo & Company. They now have a $35.00 price target on the stock.
4/1
12:05 pm
avte
Rating for AVTE
Medium
Report
Rating for AVTE
4/1
12:05 pm
avte
Rating for AVTE
Medium
Report
Rating for AVTE
3/25
08:37 am
avte
Rating for AVTE
Low
Report
Rating for AVTE
3/25
08:37 am
avte
Rating for AVTE
Low
Report
Rating for AVTE